<DOC>
	<DOC>NCT01426906</DOC>
	<brief_summary>A Randomized, Open Label, Drug-Drug interaction study to investigate effect of ketoconazole or rifampicin on the Pharmacokinetic characteristics and safety of LC15-0444 in Healthy Male Volunteers.</brief_summary>
	<brief_title>Pharmacokinetic Drug Interaction Study in Healthy Male Subjects</brief_title>
	<detailed_description>This study is a randomized, open-label, 2-period, 3-treatment, 1-sequence, drug-drug interaction study in healthy volunteers to evaluate effect of ketoconazole or rifampicin on the PK characteristic and safety of LC15-0444. Eligibility for participation of this study will be determined by demographic information, medical history, physical examination, electrocardiogram (ECG) and clinical laboratory tests within 4 weeks(-28 d ~ -2 d) before the first drug administration(1 d). Eligible subjects will be randomized to one of study treatment groups. According to the characteristics of anti-diabetic drugs, it is expected to be administered with other drugs in many patients. Therefore, Drug-Drug Interaction with CYP3A4 inducer and inhibitor should be identified in this trial.</detailed_description>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Is a healthy male between 20 and 50 years old Has BMI result between 19 and 26 kg/m2 at screening; and a total body weight over 55 kg. BMI(kg/m2) = body weight(kg)/{height(m)}2. Is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures Agrees to use an adequate means of contraception during clinical trials Subjects with evidence or history of clinically significant hepatic, renal, digestive, neurologic, pulmonary, musculoskeletal, endocrine, hematological, cardiovascular or psychiatric disease Subjects with evidence or history of gastrointestinal disease or surgery possibly affecting drug absorption. Subjects with history of hypersensitivities or clinically significant adverse events caused by DPPIV inhibitors, ketoconazole, rifampicin, and other drugs Subjects who have donated a unit of blood within 60 days or blood components within 30 days before the first administration of the investigational product. Subjects who consume excessive alcohol or caffeine; who excessively smoke</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>